Medtronic entered into a definitive agreement to acquire Titan Spine, a titanium spine interbody implant and surface technology company. Financial terms are not being disclosed.
With the purchase, Medtronic will acquire Titan’s complete portfolio of titanium surface-enhanced interbody devices. Medtronic leadership believes their biologics paired with Titan’s nanoLock surface enhanced devices can have a positive impact on patient outcomes. The deal is expected to close during Medtronic’s first fiscal quarter ending July 26, 2019, and will not have a material impact on 2020 earnings.
News of the deal comes on the heels of Medtronic’s February 2019 shuttering of Responsive Orthopedics, a start-up they acquired to provide low-cost knee and hip implants designed for bundled payments. Amid ongoing price pressure in those segments, Medtronic determined that it was not able to offer disruptive pricing.
Medtronic entered into a definitive agreement to acquire Titan Spine, a titanium spine interbody implant and surface technology company. Financial terms are not being disclosed.
With the purchase, Medtronic will acquire Titan’s complete portfolio of titanium surface-enhanced interbody devices. Medtronic leadership believes their biologics paired...
Medtronic entered into a definitive agreement to acquire Titan Spine, a titanium spine interbody implant and surface technology company. Financial terms are not being disclosed.
With the purchase, Medtronic will acquire Titan’s complete portfolio of titanium surface-enhanced interbody devices. Medtronic leadership believes their biologics paired with Titan’s nanoLock surface enhanced devices can have a positive impact on patient outcomes. The deal is expected to close during Medtronic’s first fiscal quarter ending July 26, 2019, and will not have a material impact on 2020 earnings.
News of the deal comes on the heels of Medtronic’s February 2019 shuttering of Responsive Orthopedics, a start-up they acquired to provide low-cost knee and hip implants designed for bundled payments. Amid ongoing price pressure in those segments, Medtronic determined that it was not able to offer disruptive pricing.
Copy to clipboard 
